Radnostix Stock Price, News & Analysis

International Isotopes Inc. (INIS), now operating under the corporate name Radnostix, Inc. following a formal name change, is a Texas-incorporated company that trades on the OTCQB marketplace under the ticker symbol INIS. Established in 1995 and headquartered in Idaho Falls, Idaho, the company focuses on manufacturing and supplying radioisotope-centered products and related technologies. According to its own descriptions and SEC filings, the business has evolved from an emphasis on radiochemicals and non-medical radioisotopes to a broader portfolio of radioisotope, theranostics, and related products, devices, and accessories, mainly focused on healthcare applications.

The company reports several primary business segments, reflecting its product and service mix. These segments include Theranostics Products, Calibration & Reference Products (previously referred to as Nuclear Medicine Standards), Cobalt Products, and Medical Devices. In addition, it has historically maintained a Fluorine Products segment related to a proposed de-conversion facility, although recent disclosures indicate no sales in that segment and a pending asset sale.

Theranostics Products

The Theranostics Products segment centers on radioisotope-based pharmaceutical products and active pharmaceutical ingredients (APIs). The company states that it manufactures and supplies generic sodium iodide I-131 radiopharmaceutical drug product used for hyperthyroidism and thyroid cancer, as well as I-131 theranostic API products that are used in radiolabeling third-party drug products. Public disclosures describe ongoing demand for these I-131 products and note that they are used in theranostic applications, linking diagnostic and therapeutic uses of radioisotopes.

INIS also provides contract manufacturing of various drug products and radioisotope API supply for third-party theranostics clients. These activities position the company as a manufacturing and supply partner to other organizations developing or commercializing radiopharmaceutical and theranostic products.

Calibration & Reference Products (RadQual and PhanQual)

The segment now reported as Calibration & Reference Products focuses on standards and sources used in nuclear medicine and related fields. The company reports that it manufactures and distributes a complete line of calibration and reference standards for nuclear pharmacies and SPECT/PET imaging systems, as well as industrial calibration standards. Many of these products are marketed under the RadQual brand, a wholly owned subsidiary that designs, develops, manufactures, and globally distributes sealed calibration and reference sources for medical, laboratory, industrial, research, and scientific applications.

INIS has also formed a joint venture with Phantech Medical to create PhanQual, which is intended to design, manufacture, and distribute long-lived calibration and reference sources for pre-clinical imaging applications. Disclosures state that PhanQual will combine INIS’s sealed source and radioisotope capabilities with Phantech’s phantom and fillable calibration source technologies, with RadQual distributing Phantech’s portfolio of fillable sources through its global distributor network.

Cobalt Products

Within its Cobalt Products segment, International Isotopes manufactures Cobalt-60 sealed source products. Company releases repeatedly note that it is the only domestic United States manufacturer of high activity Cobalt-60 sealed-source products. These products are sold in large-value transactions that can be seasonal and can significantly affect period-to-period comparisons, as described in multiple earnings announcements.

Medical Devices and RadVent / EasyFill

The company has established a Medical Devices segment, which it identifies as a newer reportable segment. This segment is focused, according to company statements, on bringing products to market that help improve safety, efficiency, and patient access to radiopharmaceutical diagnostics and therapeutics. The Medical Devices segment includes products under the RadVent brand, such as The Swirler®, Tru-Fit™ Mouthpiece, and Xenon System with related accessories. These products were expanded through an amended asset purchase agreement with AMICI, Inc., under which INIS obtained manufacturing molds, device registrations, trademarks, and production rights to the Xenon System products and the intellectual property for Swirler® and Tru-Fit™ Mouthpiece products.

The company also reports investment in a joint venture for the EasyFill Automated Iodine Capsule System, and in some disclosures notes distribution and servicing agreements for Scintomics ATT products and Global Sonics products in connection with this segment. The Medical Devices segment is described as being in a buildout and commercialization phase, with ongoing investment in product development and market introduction.

Fluorine Products and Asset Sale

INIS has historically maintained a Fluorine Products segment related to a proposed de-conversion facility. Recent financial reports indicate that there have been no sales in this segment for the reported periods, with expenses limited to maintenance of plans, designs, and other assets. The company has entered into an asset sale agreement for this segment and has reported extension payments and a joint consent request to the U.S. Nuclear Regulatory Commission (NRC) to transfer a license to the buyer, with an expected closing by a stated milestone.

Corporate Evolution and Name Change to Radnostix, Inc.

In an 8-K filing and accompanying press release, the company disclosed that on December 23, 2025 it filed a Certificate of Amendment in Texas to change its corporate name from International Isotopes Inc. to Radnostix, Inc.. The stated reason for the name change is that the business has expanded from radiochemicals and non-medical radioisotopes, with an energy-sector focus, to a broader portfolio of radioisotope, theranostics, and related products, devices, and accessories, mainly focused on healthcare applications. The company indicates that the Radnostix name better reflects this focus on radioisotopes and theranostics.

Following the name change, the company has stated that it will rebrand operations under the Radnostix name, while continuing to use the INIS branding around segments focused on high energy sources, bulk radioisotopes, and stable isotopes. Other brands, including RadQual, RadVent, EasyFill, Benchmark, and PhanQual, are described as continuing under the Radnostix, Inc. umbrella. The 8-K filing notes that, at the time of the filing, the common stock continues to trade under the ticker symbol INIS on the OTCQB marketplace, with no required action by shareholders regarding stock certificates as a result of the name change.

Geographic Base and Facilities

International Isotopes / Radnostix reports that it is headquartered in Idaho Falls, Idaho, USA. In a facility-related announcement, the company described purchasing vacant land adjacent to its existing Idaho Falls facility (referred to as Building A) and entering into a lease agreement, with a right of purchase, for a second building (Building B) located across the street from its current facility. The company indicates that the Building B lease is intended to provide near-term capability to approximately double operational capacity across existing business segments, while the acquired lot for Building A is intended to support potential construction of a significantly larger facility as part of a longer-term growth plan.

International Partnerships and Joint Ventures

The company has publicly disclosed several partnerships and joint ventures that extend its reach beyond its Idaho base. It reports a manufacturing joint venture with Alpha Nuclides intended to bring INIS and RadQual products into China via an entity referred to as Radnostix China. In addition, the PhanQual joint venture with Phantech Medical focuses on pre-clinical calibration sources, combining INIS’s sealed source manufacturing and RadQual’s distribution network with Phantech’s phantom and fillable source technologies.

Corporate Governance and Regulatory Context

As a reporting company under the Securities Exchange Act of 1934, International Isotopes Inc. (now Radnostix, Inc.) files periodic and current reports with the U.S. Securities and Exchange Commission (SEC). Recent 8-K filings describe governance developments such as an employment agreement with the company’s President and Chief Executive Officer, changes to bylaws regarding special meetings, advance notice procedures for shareholder business and director nominations, the ability to appoint advisory directors, provisions for indemnification and insurance, and the ability of shareholders to take action by less than unanimous written consent. The company also reports the appointment of an independent director with nuclear pharmacy and radiopharmaceutical manufacturing experience to its board and audit committee.

In multiple earnings releases, the company discusses the use of non-GAAP financial measures such as EBITDA and Adjusted EBITDA, explaining that these are supplemental to GAAP results and used by management to analyze financial performance. It emphasizes that these measures should not be considered alternatives to GAAP measures and may not be comparable to similar measures used by other companies.

Business Model and Segment Interactions

Across its segments, International Isotopes / Radnostix presents itself as a manufacturer and supplier of radioisotope-based products, radiopharmaceuticals, sealed sources, calibration standards, and related medical devices. The Theranostics Products segment provides radiopharmaceutical drug products and APIs, while the Calibration & Reference Products segment supports nuclear pharmacies, imaging systems, and industrial users through RadQual and PhanQual offerings. The Cobalt Products segment manufactures Cobalt-60 sealed sources, and the Medical Devices segment focuses on devices and systems that support radiopharmaceutical diagnostics and therapeutics, including RadVent-branded products and the EasyFill Automated Iodine Capsule System joint venture.

Company disclosures also highlight the impact of global isotope supply dynamics—such as shortages of Cobalt-57 and Gadolinium-153—on certain product lines, as well as the seasonal nature and timing of large Cobalt-60 sealed source sales. These factors are described as influencing revenue patterns across reporting periods.

Stock Information and Ticker Symbol

According to SEC filings and company press releases, the company’s common stock is quoted on the OTCQB marketplace under the ticker symbol INIS. Following the legal name change to Radnostix, Inc., the company has stated that the ticker symbol remains INIS at this time, and that any potential change in trading symbol would be announced separately. No delisting or deregistration filings are referenced in the provided materials.

Summary

In summary, International Isotopes Inc., now known corporately as Radnostix, Inc., is a U.S.-based manufacturer and supplier of radioisotope-focused products, radiopharmaceuticals, calibration standards, Cobalt-60 sealed sources, and medical devices, with multiple operating segments and brands including RadQual, RadVent, EasyFill, Benchmark, and PhanQual. Its evolution toward a theranostics and healthcare-focused portfolio is reflected in its rebranding, product mix, and reported investments in facilities, joint ventures, and new product development.